Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins

• DOI: 10.1371/journal.pone.0138332
• Publication Date: 2015-09-23T18:12:43Z
• Authors: Kentaro Sakamoto; Mitsunobu Kawamura; Takahide Kohro; Masao Omura; Takayuki Watanabe; Keiko Ashidate; Toshiyuki Horiuchi; Hidehiko Hara; Nobuo Sekine; Rina Chin; Motoyoshi Tsujino; Toru Hiyoshi; Motoki Tagami; Akira Tanaka; Yasumichi Mori; Takeshi Inazawa; Tsutomu Hirano; Tsutomu Yamazaki; Teruo Shiba
• Keywords: Ezetimibe

Background There exists a subpopulation of T2DM in whom first-line doses statin are insufficient for optimally reducing LDL-C, representing major risk CVD. The RESEARCH study focuses on LDL-C reduction this population along with modifications the lipid profiles leading to residual risks. Methods Lipid changes were assessed randomized, multicenter, 12-week, open-label comparing high-potency (10mg atorvastatin or 1mg pitavastatin) plus ezetimibe (EAT: n = 53) double dose (20mg 2mg (DST: 56) DM subjects who had failed achieve optimal targets. variables compared primary focus and secondary percentage patients reached targets levels RLP-C (remnant like particle cholesterol) sd-LDL-C, two characteristic atherogenic risks DM. Results (%), endpoint, differed significantly between groups (-24.6 EAT vs. -10.9 DST). In analyses endpoints, treatment brought about larger reductions sd-LDL-C (-20.5 -3.7) (-19.7 +5.5). total, 89.4% receiving optimized goal 51.0% DST. TC (-16.3 -6.3) non-HDL-C (-20.7 -8.3) groups. Conclusion Ezetimibe added (10 mg 1 was more effective than intensified-dose (20 2 not only helping attain reduction, but also improving their profiles, including RLP-C. We thus recommend addition as first line strategy response. Trial Registration UMIN Clinical Trials Registry UMIN000002593